Literature DB >> 26888693

Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients.

Fortunato Ciardiello1, Richard Adams2, Josep Tabernero3, Thomas Seufferlein4, Julien Taieb5, Vladimir Moiseyenko6, Brigette Ma7, Gustavo Lopez8, Johan F Vansteenkiste9, Regina Esser10, Sabine Tejpar11.   

Abstract

BACKGROUND: Two separate multinational surveys of oncologists and patients with cancer were conducted to assess the awareness and use of biomarkers in clinical practice. These data explore the self-reported and physician-assessed levels of patient cancer literacy and factors affecting physicians' choice to use biomarkers in treatment decisions. PATIENTS AND METHODS: Interviews were conducted via telephone with patients and online with physicians. Physicians had 3-35 years of experience; were treating more than 15 patients/month; and specialized in breast, lung, or colorectal cancer. Patients had received treatment for breast, lung, or colorectal cancer within the previous 5 years.
RESULTS: Interviews with 895 physicians and 811 patients were completed. Most patients and physicians reported that patients understood that a tumor could be tested to determine what treatment would be most effective (78% and 73%, respectively) and that patients would be willing to participate in a personalized treatment plan. Whereas 85% of patients felt that they understood their treatment when it was explained to them, only 23% of doctors felt that their patients were always fully informed. Most physicians (90%) reported using biomarkers; among the 10% not performing biomarker analysis, the most cited obstacles were local availability, speed of obtaining results, and cost.
CONCLUSION: These data demonstrate wide global use of biomarker testing but with regional variations reflecting cultural and local practice. Self-reported and physician-assessed cancer literacy, although generally high, highlighted important regional variations and the need to provide patients with additional information. ©AlphaMed Press.

Entities:  

Keywords:  Biomarkers; Colorectal cancer; Individualized medicine; Personalized medicine; Surveys

Mesh:

Substances:

Year:  2016        PMID: 26888693      PMCID: PMC4786350          DOI: 10.1634/theoncologist.2015-0279

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  18 in total

1.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Authors:  Jean-Yves Douillard; Salvatore Siena; James Cassidy; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; György Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean-Luc Canon; Mark Rother; Kelly S Oliner; Michael Wolf; Jennifer Gansert
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

Review 2.  Cancer genomics: technology, discovery, and translation.

Authors:  Ben Tran; Janet E Dancey; Suzanne Kamel-Reid; John D McPherson; Philippe L Bedard; Andrew M K Brown; Tong Zhang; Patricia Shaw; Nicole Onetto; Lincoln Stein; Thomas J Hudson; Benjamin G Neel; Lillian L Siu
Journal:  J Clin Oncol       Date:  2012-01-23       Impact factor: 44.544

3.  FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.

Authors:  C Bokemeyer; C-H Köhne; F Ciardiello; H-J Lenz; V Heinemann; U Klinkhardt; F Beier; K Duecker; J H van Krieken; S Tejpar
Journal:  Eur J Cancer       Date:  2015-04-30       Impact factor: 9.162

4.  The precision medicine initiative: a new national effort.

Authors:  Euan A Ashley
Journal:  JAMA       Date:  2015-06-02       Impact factor: 56.272

5.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

Review 6.  Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes.

Authors:  Joan Prades; Eline Remue; Elke van Hoof; Josep M Borras
Journal:  Health Policy       Date:  2014-09-18       Impact factor: 2.980

7.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

Authors:  Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

Review 8.  Clonal evolution in cancer.

Authors:  Mel Greaves; Carlo C Maley
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

9.  Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.

Authors:  Eric Van Cutsem; Heinz-Josef Lenz; Claus-Henning Köhne; Volker Heinemann; Sabine Tejpar; Ivan Melezínek; Frank Beier; Christopher Stroh; Philippe Rougier; J Han van Krieken; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

Review 10.  Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.

Authors:  Sai-Hong Ignatius Ou
Journal:  Drug Des Devel Ther       Date:  2011-11-23       Impact factor: 4.162

View more
  11 in total

1.  The Role of the Health Care Provider in Building Trust Between Patients and Precision Medicine Research Programs.

Authors:  Anitra Persaud; Vence L Bonham
Journal:  Am J Bioeth       Date:  2018-04       Impact factor: 11.229

Review 2.  The current state of molecular testing in the treatment of patients with solid tumors, 2019.

Authors:  Wafik S El-Deiry; Richard M Goldberg; Heinz-Josef Lenz; Anthony F Shields; Geoffrey T Gibney; Antoinette R Tan; Jubilee Brown; Burton Eisenberg; Elisabeth I Heath; Surasak Phuphanich; Edward Kim; Andrew J Brenner; John L Marshall
Journal:  CA Cancer J Clin       Date:  2019-05-22       Impact factor: 508.702

Review 3.  Patient and public understanding of the concept of 'personalised medicine' in relation to cancer treatment: a systematic review.

Authors:  Jed Botham; Valerie Shilling; John Jones
Journal:  Future Healthc J       Date:  2021-11

Review 4.  Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer.

Authors:  Mark Lawler; Deborah Alsina; Richard A Adams; Annie S Anderson; Gina Brown; Nicola S Fearnhead; Stephen W Fenwick; Stephen P Halloran; Daniel Hochhauser; Mark A Hull; Viktor H Koelzer; Angus G K McNair; Kevin J Monahan; Inke Näthke; Christine Norton; Marco R Novelli; Robert J C Steele; Anne L Thomas; Lisa M Wilde; Richard H Wilson; Ian Tomlinson
Journal:  Gut       Date:  2018-01       Impact factor: 23.059

Review 5.  Ethical considerations of neuro-oncology trial design in the era of precision medicine.

Authors:  Saksham Gupta; Timothy R Smith; Marike L Broekman
Journal:  J Neurooncol       Date:  2017-05-29       Impact factor: 4.130

6.  Cancer Patient-Reported Preferences and Knowledge for Liquid Biopsies and Blood Biomarkers at a Comprehensive Cancer Center.

Authors:  Min Joon Lee; Katrina Hueniken; Nathan Kuehne; Lin Lu; Shirley Xue Jiang; Badr Id Said; Alex McCartney; Yizhuo Gao; Mindy Liang; Tamara Obuobi; Hadas Sorotsky; Lawson Eng; M Catherine Brown; Wei Xu; Geoffrey Liu
Journal:  Cancer Manag Res       Date:  2020-02-13       Impact factor: 3.989

Review 7.  Precision Medicine in Lymphoma by Innovative Instrumental Platforms.

Authors:  Antonello Di Paolo; Elena Arrigoni; Giacomo Luci; Federico Cucchiara; Romano Danesi; Sara Galimberti
Journal:  Front Oncol       Date:  2019-12-17       Impact factor: 6.244

8.  Patterns of Biomarker Use in Cancer Treatment Among Medical Oncologists in the Philippines.

Authors:  Lance Isidore Catedral; Harold Nathan Tan; Alfredo Chua; Danielle Benedict Sacdalan; Dennis L Sacdalan
Journal:  JCO Glob Oncol       Date:  2020-10

9.  The Avatar Acceptability Study: Survivor, Parent and Community Willingness to Use Patient-Derived Xenografts to Personalize Cancer Care.

Authors:  C E Wakefield; E L Doolan; J E Fardell; C Signorelli; V F Quinn; K M Tucker; A F Patenaude; G M Marshall; R B Lock; G Georgiou; R J Cohn
Journal:  EBioMedicine       Date:  2018-10-29       Impact factor: 8.143

10.  A Quantitative Framework for Measuring Personalized Medicine Integration into US Healthcare Delivery Organizations.

Authors:  Arushi Agarwal; Daryl Pritchard; Laura Gullett; Kristen Garner Amanti; Gary Gustavsen
Journal:  J Pers Med       Date:  2021-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.